8:15 am Check-In, Coffee & Light Breakfast

8:50 am Chair’s Opening Remarks

  • Kashif Khan Director, Medicinal Chemistry, Tumor Targeted Delivery, AstraZeneca

Leveraging Degraders as ADC Payloads: Balancing Safety & Efficacy

9:00 am Exploring the PROxAb Shuttle: A Plug & Play Solution for Targeted Antibody-Mediated PROTAC Delivery


  • Displaying how targeting delivery of PROTACs via antibodies improves both safety and PK profiles
  • Leveraging the PROxAb Shuttle as a Plug&Play technology that enables targeted delivery of PROTACs without any PROTAC modification
  • Validating PROxAb Shuttles in-vivo and generating within only a few weeks

9:30 am Uncovering Protein Homeostasis by Dual Precision Approach & Development of a Novel Catalytic Payload Class With an Improved Safety and Efficacy Profile & Exploring Diversity of degrader SAR

  • Greg Dwyer Vice President, Head of Business Development, Orum Therapeutics


  • Development of a novel, catalytic payload class leveraging catalytic enzmes to disrupt cellular processes
  • Exploring the diversity of degrader SAR studies while also enabling conjugation to targeting format
  • Improving potency and selectivity of delivery to target cells with catalytic action allowing for lower payload doses

10:00 am Morning Coffee & Refreshments Break

Exploring Novel Approaches for Anti-Tumor Treatment via ADC Payload Mechanism of Action & Dual Payload Approaches

11:00 am Roundtable Discussion – Exploring Potential of ADC Payloads: Small Molecule Cytotoxins, DNA Damaging Agents, PROTACS & Oligonucleotides


  • Discussing payload delivery through TM4SF1-guided new internalization mechanism of action
  • Uncovering the potential ADC payloads: small molecule cytotoxins or DNA damaging agents, PROTACs (degrader), and oligonucleotides (ASO or siRNA)
  • Leveraging tumor endothelium targeting to improve ADC payload efficacy

11:30 am The Surge in Discovery and Development of Novel Topoisomerase Inhibitor Payloads. Overcoming Challenges in Process Development and Manufacturing of the Next Generation Camptothecin-Based Linker-Payloads


  • Recent trends in discovery of novel payloads for ADCs
  • Successful CRO partnerships to discover and develop next-generation camptothecin-based payloads.
  • Design and development of robust synthetic processes for manufacturing the next generation linker-payloads for conjugates.

11:45 am Targeting KIF20A Kinesin: A Promising Strategy for Next-Generation ADC Payload


  • Presenting EVX-020, a first-in-class highly selective KIF20A inhibitor
  • Sharing nonclinical efficacy data of EVX-020 in tumor models and the involvement of KIF20A in Golgi Function
  • Analyzing the MoA of EVX-020, and its potential as a new ADC payload

12:15 pm Lunch

Further Progressing TOPI Inhibitor Payloads to Improve Tumor Specificity & Leveraging SARs to Optimize Payloads

1:15 pm Expanding Selection of Tubulin & TOPI Inhibitor Payloads for Improved Tumor Specific Delivery by Peptide Drug Conjugate


  • Considering the stability of linker-warhead peptide conjugates when working with TOPI inhibitor and tubulin inhibitors
  • Improving tumor specificity of warhead delivery for improved therapeutic window
  • Describing preclinical efficacy and safety profile, both clinical and non-clinical for Auristatin and Topo1 assets

Navigating Current ADC Payload Trends & Predicting the Future of the ADC Payload Field

1:45 pm Panel: Considering Future Clinical Applicability of Novel Payloads Currently in Discovery



  • Thinking about the future of the clinical landscape in comparison to now, and what the most promising novel payload contenders are
  • Realizing feasibility of some novel payloads: thinking about developmental or future safety concerns with novel mechanisms of action
  • Identifying gaps for development of novel payloads from the current landscape

2:20 pm End of Conference

2:45 pm Chair’s Closing Remarks

  • Kashif Khan Director, Medicinal Chemistry, Tumor Targeted Delivery, AstraZeneca